Health · Pharma & Biotech · 2 hrs ago

Amplia receives ethics approval for pancreatic cancer drug trial

Amplia receives ethics approval for pancreatic cancer drug trial

Amplia Therapeutics has ethics approval to begin a trial of its drug narmafotinib with chemotherapy in people with metastatic pancreatic cancer.

The company plans to recruit patients at three Australian clinical trial sites for the ACCENT-Mini study.

Narmafotinib blocks a protein called FAK, which can help form dense tissue around tumours; Amplia hopes this may help chemotherapy reach cancer cells.

The trial follows an earlier study that reported a 36 per cent confirmed tumour response rate, but ACCENT-Mini will test a daily dosing schedule to find a safe and effective dose.

Safety and drug-level data are expected in early 2027, according to the company.

Amplia plans to use those results in a submission to the US Food and Drug Administration for a larger study, if the findings support moving ahead.

1 source

Related

What people are saying

Dr Chris BurnsAmplia Therapeutics chief executive officer and managing director
We are delighted to have received ethics approval for this important study of narmafotinib in metastatic pancreatic cancer, a devastating disease where patients have limited treatment options.
via SMH
Based on our preclinical studies and clinical experience to date, we believe that combining chemotherapy with daily-dosed narmafotinib has the potential to deliver improved outcomes, and we look forward to exploring this in ACCENT-Mini.
via SMH